{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-081485","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.888789+00:00","generated_at":"2026-06-17T13:26:33.206164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sensei Biotherapeutics reports FY2022 net loss of $48.6M; cash runway into H2 2025","bullets":["Net loss $48.6M vs $36.8M in 2021; loss per share $1.58.","Cash and securities $107.1M at Dec 31, 2022, down from $147.6M.","IND submitted for lead candidate SNS-101 (VISTA-blocking antibody) in March 2023.","New collaborations with Regeneron, NCI, and WashU to support SNS-101 development.","Expects to select candidates for SNS-102 and SNS-103 in 2023; cash runway into H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-081485","json":"https://secwatch.observer/filing/0001193125-23-081485.json","markdown":"https://secwatch.observer/filing/0001193125-23-081485.md","text":"https://secwatch.observer/filing/0001193125-23-081485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/0001193125-23-081485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/d466084d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:26:33.206164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e168b60b0afc4e780ae77602d2028235f3d7e446","claim":"Sensei Biotherapeutics, Inc. reported financial results for the full year ended December 31, 2022.","evidence_excerpt":"On March 28, 2023, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523081485/0001193125-23-081485-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}